Viscosupplementation Market, By Dosage (Single Injection, Three Injection, and Five Injection), By Arthritis Type (Osteoarthritis and Rheumatoid Arthritis), By End User (Hospitals, Specialty Clinics, Ambulatory Surgical Centers, and Others), By Geography

Global viscosupplementation market is estimated to be valued at USD 4.15 Bn in 2025 and is expected to exhibit a CAGR of 8% during the forecast period (2025-2032). Viscosupplementation is an orthopedic treatment method used to manage osteoarthritis knee pain. It involves injecting hyaluronic acid, also known as hyaluronan, into the knee joint. Hyaluronic acid acts as a lubricant and shock absorber in the joints. It replenishes levels in the joint that diminish with osteoarthritis. This helps reduce pain and improve mobility by supplementing the viscous nature of the synovial fluid in knees affected by osteoarthritis. Viscosupplementation therapy is a non-surgical treatment option that provides relief from knee osteoarthritis symptoms for extended periods of time.

Market Dynamics

The global viscosupplementation market is driven by the rising geriatric population which is more prone to develop osteoarthritis and the associated joint pains. As per estimates, over 330 million people currently suffer from osteoarthritis globally. This is projected to increase substantially in the coming years. Moreover, growing awareness about advanced non-invasive treatment alternatives and favorable reimbursement policies for viscosupplementation procedures are boosting the market. However, the market growth can be restrained by the preference for alternative treatment methods like dietary supplements and limitations in the efficacy and duration of pain relief provided by hyaluronic acid injections. The integration of 3D printing and robotic technologies to develop patient-specific hyaluronic acid formulations provides lucrative opportunities in this market.

Key Features of the Study

• This report provides in-depth analysis of the global viscosupplementation market, and provides market size (USD Bn) and compound annual growth rate (CAGR%) for the forecast period (2025–2032), considering 2024 as the base year.
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
• It profiles key players in the global viscosupplementation market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies.
• Key companies covered as a part of this study includes Anika Therapeutics Inc., Seikagaku Corporation, Ferring Pharmaceuticals, Bioventus, Fidia Farmaceutici S.P.A., Mylan N.V., Sanofi S.A., OrthogenRx, Teva Pharmaceutical Industries Ltd, Johnson & Johnson., F. Hoffmann-La Roche AG, Zimmer Biomet, Aptissen, Wellchem Pharmaceuticals Pte Ltd., Juniper Biologics, and Ono Pharmaceutical Co., Ltd.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
• The global viscosupplementation market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global viscosupplementation market.

• Dosage Insights (Revenue, USD BN, 2020 - 2032)
• Single Injection
• Three Injection
• Five Injection
• Arthritis Type Insights (Revenue, USD BN, 2020 - 2032)
• Osteoarthritis
• Rheumatoid Arthritis
• End User Insights (Revenue, USD BN, 2020 - 2032)
• Hospitals
• Specialty Clinics
• Ambulatory Surgical Centers
• Others
• Regional Insights (Revenue, USD BN, 2020 - 2032)
• North America
• U.S.
• Canada
• Latin America
• Brazil
• Argentina
• Mexico
• Rest of Latin America
• Europe
• Germany
• U.K.
• Spain
• France
• Italy
• Russia
• Rest of Europe
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• ASEAN
• Rest of Asia Pacific
• Middle East
• GCC Countries
• Israel
• Rest of Middle East
• Africa
• South Africa
• North Africa
• Central Africa
• Key Players Insights
• Anika Therapeutics Inc.
• Seikagaku Corporation
• Ferring Pharmaceuticals
• Bioventus
• Fidia Farmaceutici S.P.A.
• Mylan N.V.
• Sanofi S.A.
• OrthogenRx
• Teva Pharmaceutical Industries Ltd.
• Johnson & Johnson
• F. Hoffmann-La Roche AG
• Zimmer Biomet
• Aptissen
• Wellchem Pharmaceuticals Pte Ltd.
• Juniper Biologics
• Ono Pharmaceutical Co., Ltd.